GUFICBIOBSEGufic Biosciences LtdMediumNeutral
Announced Fri, 29 May · 23:00 IST

Intimation for Re-appointment of Cost Auditor and Appointment of Internal Auditor is attached herewith

Management Changes View source PDF

GUFICBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+6.2%1-day move
₹332.15
prior close
₹342.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.2+0.2-1.7+2.0+6.2+9.0+6.0+12.1+13.5+9.3+7.8+18.9
Up moveDown movePending
AI summary

Gufic Biosciences' Board of Directors, meeting on May 29, 2026, approved two items: (1) Re-appointment of M/s. Poddar & Co., Cost Accountants as Cost Auditors for Financial Year 2026-27, a firm with 15 years of experience led by Sandeep Poddar serving multiple sectors including Pharmaceuticals; (2) Appointment of Mrs. Saroj R. Kirdolia as Internal Auditor from FY 2026-27, who is a Chartered Accountant with 7 years of experience and has been with the company for 6 years, responsible for evaluating internal controls and business processes. The Board meeting lasted from 7:30 PM to 9:05 PM. Both appointments were disclosed under SEBI Listing Regulations, Regulation 30 and Part A of Schedule III.

Likely market impact

These are routine governance appointments with no material impact on shareholding or leadership. The reappointment of Poddar & Co. ensures continuity in statutory cost audit compliance, while the appointment of an experienced internal auditor supports stronger internal controls and risk management.